On July 29, 2021 Patrys reported its Quarterly Activities Report and 4C for the quarter ended 30 June 2021 (Press release, Patrys, JUL 29, 2021, View Source [SID1234585449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our R&D program has continued to thrive, with significant progress in the development of our deoxymab antibodies.

Key achievements include:

New pharmacokinetic data highlighting the potential to use PAT-DX1 and PAT-DX3 for different therapeutic applications
Collaboration with Imagion Biosystems established to develop new, improved imaging agents for brain cancers using Patrys’ deoxymabs
Preclinical data supporting potential for PAT-DX1 to be used for primary and secondary brain cancers published in peer-reviewed scientific journal
The Company has a strong financial position, with cash and short-term investment balance of $10.9 M on 30 June 202, following the receipt of $627k from the R&D Tax Incentive Refund scheme.